Trial Profile
A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Serabelisib (Primary) ; Lansoprazole; Serabelisib
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 18 Mar 2017 Results assessing relative bioavailability of tablets versus capsules and the effect of dosing conditions on PK variability, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 06 Dec 2016 Status changed from not yet recruiting to completed.
- 11 Dec 2015 New trial record